- BAY1125976
-
-
2026-08-19
- CAS:1402608-02-9
- Min. Order: 1KG
- Purity: 98
- Supply Ability: 1000 KG
- BAY1125976
-
- $33.00
-
2026-07-27
- CAS:1402608-02-9
- Purity: 99.28%
- Supply Ability: 10g
|
| | BAY-1125976. Basic information |
| Product Name: | BAY-1125976. | | Synonyms: | 2-[4-(1-Aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide;BAY-1125976; BAY 1125976;CS-2913;BAY 1125976;BAY1125976;BAY-1125976.;Imidazo[1,2-b]pyridazine-6-carboxamide, 2-[4-(1-aminocyclobutyl)phenyl]-3-phenyl-;inhibit,Inhibitor,Protein kinase B,Akt,BAY 1125976,BAY1125976,PKB,BAY-1125976 | | CAS: | 1402608-02-9 | | MF: | C23H21N5O | | MW: | 383.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1402608-02-9.mol |  |
| | BAY-1125976. Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:13.0(Max Conc. mg/mL);33.9(Max Conc. mM)
DMF:5.0(Max Conc. mg/mL);13.04(Max Conc. mM)
DMF:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.65(Max Conc. mM) | | form | A crystalline solid | | color | Light yellow to yellow | | InChI | InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29) | | InChIKey | JBGYKRAZYDNCNV-UHFFFAOYSA-N | | SMILES | C12=NC(C3=CC=C(C4(N)CCC4)C=C3)=C(C3=CC=CC=C3)N1N=C(C(N)=O)C=C2 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | BAY-1125976. Usage And Synthesis |
| Description | BAY-1125976 is an allosteric inhibitor of Akt1 and -2 (IC50s = 5.2 and 18 nM, respectively, in a time-resolved FRET assay). It is selective for Akt1 and -2 over Akt3 (IC50 = 427 nM in the same assay) but does inhibit the activity of the receptor tyrosine kinases FLT1, -3, -4, and Mer by greater than 50% in a panel of 227 kinases at 1 μM. BAY-1125976 inhibits the proliferation of 23 cancer cell lines (IC50s = 0.02-10 μM) and reduces tumor growth in KPL-4, MCF-7, and patient-derived xenograft (PDX) mouse models when administered at a dose of 50 mg/kg per day. | | Uses | BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively. | | in vivo | BAY 1125976 targets tumors displaying activation of the PI3K/Akt/mTOR pathway. BAY 1125976 exhibits strong in vivo efficacy in both cell line and patient-derived xenograft models such as the KPL4 breast cancer model (PIK3CAH1074R mutant), the MCF7 and HBCx-2 breast cancer models, and the AktE17K mutant driven prostate cancer (LAPC-4) and anal cancer (AXF 984) models[1]. | | IC 50 | Akt1: 5.2 nM (IC50, at 10 μM ATP); Akt2: 18 nM (IC50, at 10 μM ATP); Akt3: 427 nM (IC50, at 10 μM ATP) | | References | [1] Politz O, et al. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. Int J Cancer. 2017 Jan 15;140(2):449-459. DOI:10.1002/ijc.30457 |
| | BAY-1125976. Preparation Products And Raw materials |
|